We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Needle Length In Obese Insulin-Using Diabetic Subjects (INOBESE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00541372
Recruitment Status : Completed
First Posted : October 10, 2007
Last Update Posted : March 17, 2009
Martini Hospital Groningen
Information provided by:
University Medical Center Groningen

Brief Summary:
For the administration of insulin, different needles are available with a length from 5 to 12.7mm. Insulin injections with a needle of 8 mm is injected in a lifted skinfold, a 5 mm needle can by used without lifting a skinfold (1). In the Netherlands obese people (BMI ≥ 30) are usually advised to use an 8mm or even longer needle (1). Increased BMI and the thickness of the subcutaneous tissue slow insulin absorption (2, 3, 4), possibly related to reduced subcutaneous blood flow. Furthermore, the capillaries are located just under the skin and between the fat and muscle layer. This could possibly determine the absorbing speed (2). It is not know if the administration of insulin with a 5mm needle by obese people has a different influence on the HbA1c compared to longer needles. The hypothesis of this study is that for the purpose of insulin injections, a 5 mm needle can be used without negative effects on metabolic parameters in patients with Diabetes Mellitus (DM) and a Body Mass Index (BMI) ≥ 30.

Condition or disease Intervention/treatment Phase
Diabetes Mellitus Device: insulin injection needle size Phase 4

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 130 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: The Influence of the Needle Length on Long Term Glycaemic Control in Insulin Using Obese Diabetic Subjects
Study Start Date : September 2007
Primary Completion Date : March 2009
Study Completion Date : March 2009

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: 1
Needle 5 mm
Device: insulin injection needle size
The intervention in this study is a specific needle with a length of 5 mm and 8 mm to be used with an insulin pen.
Active Comparator: 2
Needle length 8 mm
Device: insulin injection needle size
The intervention in this study is a specific needle with a length of 5 mm and 8 mm to be used with an insulin pen.

Primary Outcome Measures :
  1. Preference of the patient and amount of experienced hypoglycaemic events, bruises, backflow of insulin, bleeding and pain (VAS-scale) [ Time Frame: 4 months ]

Secondary Outcome Measures :
  1. HbA1c levels 1,5 anhydroglucitol and fructosamine levels Insulin dose [ Time Frame: 4 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male and female adult patients diagnosed with type 1 and type 2 diabetes mellitus, treated with insulin injections for at least one year and:

    • using an insulin pen
    • a BMI > 30 kg/m2
    • a skinfold thickness of >10 mm at the injection sites
    • stable glycaemic control, with HbA1c between 6 and 10%
    • capable of reading the written information
    • prepared to, and capable of signing an informed consent

Exclusion Criteria:

  • Patients who:

    • change their own insulin dosage and are not prepared to keep a record of these changes
    • have hypoglycaemia unawareness
    • are pregnant or wish to become pregnant
    • have a BMI < 30 kg/m2
    • have a skinfold thickness <10mm
    • have skin problems including lipodystrophy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00541372

University Medical Centre Groningen
Groningen, Netherlands
Sponsors and Collaborators
University Medical Center Groningen
Martini Hospital Groningen
Principal Investigator: Bruce HR Wolffenbuttel, MD PhD University Medical Center Groningen

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: B.H.R. Wolffenbuttel, Univ Med Ctr Groningen
ClinicalTrials.gov Identifier: NCT00541372     History of Changes
Other Study ID Numbers: BWO-07001
First Posted: October 10, 2007    Key Record Dates
Last Update Posted: March 17, 2009
Last Verified: March 2009

Additional relevant MeSH terms:
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Insulin, Globin Zinc
Hypoglycemic Agents
Physiological Effects of Drugs